These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

132 related items for PubMed ID: 18779378

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Cinaciguat (BAY 58-2667) improves cardiopulmonary hemodynamics in patients with acute decompensated heart failure.
    Lapp H, Mitrovic V, Franz N, Heuer H, Buerke M, Wolfertz J, Mueck W, Unger S, Wensing G, Frey R.
    Circulation; 2009 Jun 02; 119(21):2781-8. PubMed ID: 19451356
    [Abstract] [Full Text] [Related]

  • 3. Pharmacokinetics of the soluble guanylate cyclase activator cinaciguat in individuals with hepatic impairment.
    Frey R, Scheerans C, Blunck M, Mück W, Gnoth MJ, Unger S, Schmidt A, Wensing G.
    J Clin Pharmacol; 2012 Nov 02; 52(11):1714-24. PubMed ID: 22162535
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Targeting heme-oxidized soluble guanylate cyclase in experimental heart failure.
    Boerrigter G, Costello-Boerrigter LC, Cataliotti A, Lapp H, Stasch JP, Burnett JC.
    Hypertension; 2007 May 02; 49(5):1128-33. PubMed ID: 17325237
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Cinaciguat, a novel activator of soluble guanylate cyclase, protects against ischemia/reperfusion injury: role of hydrogen sulfide.
    Salloum FN, Das A, Samidurai A, Hoke NN, Chau VQ, Ockaili RA, Stasch JP, Kukreja RC.
    Am J Physiol Heart Circ Physiol; 2012 Mar 15; 302(6):H1347-54. PubMed ID: 22268103
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Population pharmacokinetics and pharmacodynamics of cinaciguat, a soluble guanylate cyclase activator, in patients with acute decompensated heart failure.
    Mueck W, Frey R.
    Clin Pharmacokinet; 2010 Mar 15; 49(2):119-29. PubMed ID: 20067336
    [Abstract] [Full Text] [Related]

  • 13. Pre-conditioning with the soluble guanylate cyclase activator Cinaciguat reduces ischaemia-reperfusion injury after cardiopulmonary bypass.
    Radovits T, Korkmaz S, Miesel-Gröschel C, Seidel B, Stasch JP, Merkely B, Karck M, Szabó G.
    Eur J Cardiothorac Surg; 2011 Feb 15; 39(2):248-55. PubMed ID: 20591683
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Structure of cinaciguat (BAY 58-2667) bound to Nostoc H-NOX domain reveals insights into heme-mimetic activation of the soluble guanylyl cyclase.
    Martin F, Baskaran P, Ma X, Dunten PW, Schaefer M, Stasch JP, Beuve A, van den Akker F.
    J Biol Chem; 2010 Jul 16; 285(29):22651-7. PubMed ID: 20463019
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Chronic Activation of Heme Free Guanylate Cyclase Leads to Renal Protection in Dahl Salt-Sensitive Rats.
    Hoffmann LS, Kretschmer A, Lawrenz B, Hocher B, Stasch JP.
    PLoS One; 2015 Jul 16; 10(12):e0145048. PubMed ID: 26717150
    [Abstract] [Full Text] [Related]

  • 20. Expression and activity of soluble guanylate cyclase in injury and repair of anti-thy1 glomerulonephritis.
    Peters H, Wang Y, Loof T, Martini S, Kron S, Krämer S, Neumayer HH.
    Kidney Int; 2004 Dec 16; 66(6):2224-36. PubMed ID: 15569311
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.